69O.F AELIS FARMA SAS EO -004
- Market cap
- EUR 11.3M
- P/E
- -
- P/B
- 5.36x
- ROE
- -144.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 69O.F undervalued?
Graham numberThe Graham number of AELIS FARMA SAS EO -004 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
AELIS FARMA SAS EO -004 fundamental analysis
No fundamental analysis for AELIS FARMA SAS EO -004 yet.
AELIS FARMA SAS EO -004 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About AELIS FARMA SAS EO -004
Aelis Farma SA, a clinical-stage biopharmaceutical company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders in France. The company owns a pipeline of pharmacological inhibitors, including AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; AEF0217, a drug candidate, which is in phase 1/2 clinical trials to treat cognitive deficits observ…
Full company profileAELIS FARMA SAS EO -004 financial statements
AELIS FARMA SAS EO -004 annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 9.08M | 3.81M | 9.05M | 2.68M | 0.00 |
| Operating Income | 2.55M | -8.52M | -6.46M | -7.74M | -6.20M |
| EBITDA | - | -14.0M | -4.58M | -6.68M | -5.58M |
| Net Income | 574K | -14.3M | -5.08M | -7.46M | -6.43M |
| EPS | 0.06 | -1.14 | -0.39 | -0.55 | -0.47 |
| Balance Sheet | |||||
| Total Assets | 28.3M | 39.2M | 26.3M | 19.7M | 12.0M |
| Total Liabilities | 27.4M | 19.4M | 13.1M | 9.59M | 7.61M |
| Shareholders' Equity | 900K | 19.8M | 13.2M | 10.1M | 4.44M |
| Cash & Short-term Investments | 24.7M | 34.4M | 20.2M | 14.1M | 8.21M |
| Cash Flow | |||||
| Operating Cash Flow | 19.0M | -13.1M | -13.0M | -11.8M | -5.35M |
| Capital Expenditure | 213K | 137K | 88.0K | 190K | 4.00K |
| Free Cash Flow | 18.8M | -13.2M | -13.0M | -12.0M | -5.36M |
| Ratios | |||||
| ROE | 63.8% | -72.2% | -38.5% | -73.7% | -144.9% |
| ROA | 2.0% | -36.4% | -19.3% | -37.8% | -53.4% |
| Net Profit Margin | 6.3% | -375.1% | -56.1% | -278.4% | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
AELIS FARMA SAS EO -004 dividends
AELIS FARMA SAS EO -004 has not paid dividends in the last 5 fiscal years.
Who owns AELIS FARMA SAS EO -004
- Insiders 36.44%
- Institutions 26.79%
- Public & others 36.77%
- Shares outstanding 13.6M
- Free float 4.07M
AELIS FARMA SAS EO -004 company profile
- Company name
- AELIS FARMA SAS EO -004
- Ticker
- 69O.F
- ISIN
- FR0014007ZB4
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 14
- Fiscal year end
- December
- Address
- 1 rue Lafaurie de Monbadon, Bordeaux, France, 33000
- Phone
- 33 5 54 54 23 27
- Website
- aelisfarma.com
About AELIS FARMA SAS EO -004
Aelis Farma SA, a clinical-stage biopharmaceutical company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders in France. The company owns a pipeline of pharmacological inhibitors, including AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; AEF0217, a drug candidate, which is in phase 1/2 clinical trials to treat cognitive deficits observed in down syndrome; and CB1-SSi, a new molecular entities to treat other CB1-dependent diseases, including several orphan diseases. Aelis Farma SA was incorporated in 2013 and is headquartered in Bordeaux, France.
AELIS FARMA SAS EO -004 management
2- Dr. Pier Vincenzo Piazza M.D., Ph.D.CEO & Director · born 1961
- Stephanie MonlezunChief Operating Officer